Craft

Insmed

Stock Price

$70.9

2024-10-29

Market Capitalization

$12.2 B

2024-10-29

Revenue

$606.4 M

FY, 2025

Insmed Summary

Company Summary

Overview
Insmed is a biopharmaceutical company. The company develops and invests in treatments for rare lung diseases. therapies that make a real difference in patients’ lives. Current product candidates utilize proprietary technology designed for the delivery of pharmaceuticals to the lung.
Type
Public
Status
Active
HQ
Bridgewater Township, NJ, US | view all locations
Website
http://www.insmed.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • William H. Lewis

    William H. Lewis, Chair and Chief Executive Officer

  • Eugene Sullivan

    Eugene Sullivan, Chief Product Strategy Officer

  • Michael Smith

    Michael Smith, Chief Legal Officer

  • Roger Adsett

    Roger Adsett, Chief Operating Officer

LocationsView all

11 locations detected

  • Bridgewater Township, NJ HQ

    United States

    757 US-202 #206

  • Paris, Île-de-France

    France

    1 Rue Favart

  • Paris, IDF

    France

    50 Rue de Paradis

  • Frankfurt am Main, HE

    Germany

    The Squaire 12

  • Dublin 2, County Dublin

    Ireland

    Fitzwilliam House, 28 Pembroke Street Upper

  • Bologna, Emilia-Romagna

    Italy

    Via Ferrarese, 3

and 5 others

Insmed Financials

Summary Financials

Revenue (Q1, 2026)
$306.0M
Gross profit (Q1, 2026)
$258.5M
Net income (Q1, 2026)
($163.6M)
Cash (Q1, 2026)
$582.2M
EBIT (Q1, 2026)
($153.3M)
Enterprise value
$12.2B

Footer menu